49
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Altered expression of Septin 9 ( SEPT9), a septin coding for multiple isoform variants, has been observed in several carcinomas, including colorectal, head and neck, ovarian and breast, compared to normal tissues. The mechanisms regulating its expression during tumor initiation and progression in vivo and the oncogenic function of its different isoforms remain elusive.

          Methods

          Using an integrative approach, we investigated SEPT9 at the genetic, epigenetic, mRNA and protein levels in breast cancer. We analyzed a panel of breast cancer cell lines, human primary tumors and corresponding tumor-free areas, normal breast tissues from reduction mammoplasty patients, as well as primary mammary gland adenocarcinomas derived from the polyoma virus middle T antigen, or PyMT, mouse model. MCF7 clones expressing individual GFP-tagged SEPT9 isoforms were used to determine their respective intracellular distributions and effects on cell migration.

          Results

          An overall increase in gene amplification and altered expression of SEPT9 were observed during breast tumorigenesis. We identified an intragenic alternative promoter at which methylation regulates SEPT9_v3 expression. Transfection of specific GFP-SEPT9 isoforms in MCF7 cells indicates that these isoforms exhibit differential localization and affect migration rates. Additionally, the loss of an uncharacterized SEPT9 nucleolar localization is observed during tumorigenesis.

          Conclusions

          In this study, we found conserved in vivo changes of SEPT9 gene amplification and overexpression during human and mouse breast tumorigenesis. We show that DNA methylation is a prominent mechanism responsible for regulating differential SEPT9 isoform expression and that breast tumor samples exhibit distinctive SEPT9 intracellular localization. Together, these findings support the significance of SEPT9 as a promising tool in breast cancer detection and further emphasize the importance of analyzing and targeting SEPT9 isoform-specific expression and function.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Conserved Role of Intragenic DNA Methylation in Regulating Alternative Promoters

          While the methylation of DNA in 5′ promoters suppresses gene expression, the role of DNA methylation in gene bodies is unclear 1–5 . In mammals, tissue- and cell type-specific methylation is present in a small percentage of 5′ CpG island (CGI) promoters, while a far greater proportion occurs across gene bodies, coinciding with highly conserved sequences 5–10 . Tissue-specific intragenic methylation might reduce, 3 or, paradoxically, enhance transcription elongation efficiency 1,2,4,5 . Capped analysis of gene expression (CAGE) experiments also indicate that transcription commonly initiates within and between genes 11–15 . To investigate the role of intragenic methylation, we generated a map of DNA methylation from human brain encompassing 24.7 million of the 28 million CpG sites. From the dense, high-resolution coverage of CpG islands, the majority of methylated CpG islands were revealed to be in intragenic and intergenic regions, while less than 3% of CpG islands in 5′ promoters were methylated. The CpG islands in all three locations overlapped with RNA markers of transcription initiation, and unmethylated CpG islands also overlapped significantly with trimethylation of H3K4, a histone modification enriched at promoters 16 . The general and CpG-island-specific patterns of methylation are conserved in mouse tissues. An in-depth investigation of the human SHANK3 locus 17,18 and its mouse homologue demonstrated that this tissue-specific DNA methylation regulates intragenic promoter activity in vitro and in vivo. These methylation-regulated, alternative transcripts are expressed in a tissue and cell type-specific manner, and are expressed differentially within a single cell type from distinct brain regions. These results support a major role for intragenic methylation in regulating cell context-specific alternative promoters in gene bodies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of the actin cytoskeleton in cancer cell migration and invasion.

            Malignant cancer cells utilize their intrinsic migratory ability to invade adjacent tissues and the vasculature, and ultimately to metastasize. Cell migration is the sum of multi-step processes initiated by the formation of membrane protrusions in response to migratory and chemotactic stimuli. The driving force for membrane protrusion is localized polymerization of submembrane actin filaments. Recently, several studies revealed that molecules that link migratory signals to the actin cytoskeleton are upregulated in invasive and metastatic cancer cells. In this review, we summarize recent progress on molecular mechanisms of formation of invasive protrusions used by tumor cells, such as lamellipodia and invadopodia, with regard to the functions of key regulatory proteins of the actin cytoskeleton; WASP family proteins, Arp2/3 complex, LIM-kinase, cofilin, and cortactin.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry.

              Methylation is one of the major epigenetic processes pivotal to our understanding of carcinogenesis. It is now widely accepted that there is a relationship between DNA methylation, chromatin structure, and human malignancies. DNA methylation is potentially an important clinical marker in cancer molecular diagnostics. Understanding epigenetic modifications in their biological context involves several aspects of DNA methylation analysis. These aspects include the de novo discovery of differentially methylated genes, the analysis of methylation patterns, and the determination of differences in the degree of methylation. Here we present a previously uncharacterized method for high-throughput DNA methylation analysis that utilizes MALDI-TOF mass spectrometry (MS) analysis of base-specifically cleaved amplification products. We use the IGF2/H19 region to show that a single base-specific cleavage reaction is sufficient to discover methylation sites and to determine methylation ratios within a selected target region. A combination of cleavage reactions enables the complete evaluation of all relevant aspects of DNA methylation, with most CpGs represented in multiple reactions. We successfully applied this technology under high-throughput conditions to quantitatively assess methylation differences between normal and neoplastic lung cancer tissue samples from 48 patients in 47 genes and demonstrate that the quantitative methylation results allow accurate classification of samples according to their histopathology.
                Bookmark

                Author and article information

                Journal
                Breast Cancer Res
                Breast Cancer Research : BCR
                BioMed Central
                1465-5411
                1465-542X
                2011
                10 August 2011
                : 13
                : 4
                : R76
                Affiliations
                [1 ]Department of Genetics, Albert Einstein College of Medicine, Yeshiva University, 1301 Morris Park Avenue, Bronx, NY 10461, USA
                [2 ]Department of Surgery, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA
                [3 ]Department of Pathology, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA
                [4 ]Department of Pathology, Albert Einstein College of Medicine, Yeshiva University, 111 East 210th Street, Bronx, NY 10467, USA
                [5 ]Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Yeshiva University, 1301 Morris Park Avenue, Bronx, NY 10461, USA
                [6 ]Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Yeshiva University, 1301 Morris Park Avenue, Bronx, NY 10461, USA
                [7 ]Centre de Recherche en Cancérologie de Marseille, Inserm U891, 27 bd Leï Roure, BP 30059, 13273 Marseille Cedex 09 France
                [8 ]Institut Paoli-Calmettes, F-13009 Marseille, 27 bd Leï Roure, BP 30059, 13273 Marseille Cedex 09 France
                [9 ]Aix-Marseille Université, F-13007 Marseille, 27 bd Leï Roure, BP 30059, 13273 Marseille Cedex 09 France
                Article
                bcr2924
                10.1186/bcr2924
                3236340
                21831286
                14386779-772c-4ca1-b633-a4b5b3232c15
                Copyright ©2011 Connolly et al.; licensee BioMed Central Ltd.

                This is an open access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 1 December 2010
                : 12 May 2011
                : 10 August 2011
                Categories
                Research Article

                Oncology & Radiotherapy
                oncogene,epigenetics,septin 9,cytoskeleton,breast cancer
                Oncology & Radiotherapy
                oncogene, epigenetics, septin 9, cytoskeleton, breast cancer

                Comments

                Comment on this article